Researchers are using the study to assess the safety and efficacy of the treatment of sufferers of acute bacterial skin and skin structure infections (ABSSSI).
In all 600 people took part in the REVIVE-1 trial. Half were given iclaprim, the remainder received an existing antibiotic called vancomycin.
Only at the end of the antibiotic course will the researchers know which group is which.
The results will be outlined in the second quarter.
The read-out from a second study, REVIVE-2, is expected in the second half.
Successful completion of the two final-stage trials should pave the way for regulatory submissions ahead of the formal green light of the drug in the US and Europe for patients with ABSSSI.
Chief executive Graham Lumsden said: "Thanks to the patients and investigators who participated in REVIVE-1, we remain on track to be able to share the first data from our phase III clinical trials in the second quarter.
“We believe that iclaprim, if approved, can be an important option for patients hospitalised with ABSSSI who also have kidney disease with or without diabetes.”
It is estimated that up to 26% of the 3.6mln ABSSSI patients hospitalised annually in the US have kidney disease.
The stock rose 6% to 26.5p. Northland Capital reckons a “positive readout” from REVIVE-1 could “would likely trigger a significant rerating of the shares”.
Analyst Vadim Alexandre reckons the Motif is worth 90p.
---ADDS SHARE PRICE & BROKER COMMENT---